Caricamento...
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
PURPOSE: TAS-102 is a novel oral agent combining the antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil (molar ratio 1:0.5). TAS-102 has shown good activity in refractory metastatic colorectal cancer with acceptable safety. No QT pr...
Salvato in:
| Pubblicato in: | Cancer Chemother Pharmacol |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Berlin Heidelberg
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4882359/ https://ncbi.nlm.nih.gov/pubmed/27151157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3031-9 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|